-
1
-
-
0038744296
-
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies
-
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130.
-
(2003)
Am J Hum Genet
, vol.72
, pp. 1117-1130
-
-
Antoniou, A.1
Pharoah, P.D.2
Narod, S.3
-
2
-
-
34248170114
-
Meta-analysis of BRCA1 and BRCA2 penetrance
-
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329–1333.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1329-1333
-
-
Chen, S.1
Parmigiani, G.2
-
3
-
-
0028330276
-
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium
-
Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343:692–695.
-
(1994)
Lancet
, vol.343
, pp. 692-695
-
-
Ford, D.1
Easton, D.F.2
Bishop, D.T.3
Narod, S.A.4
Goldgar, D.E.5
-
5
-
-
84883625609
-
Hereditary breast cancer: ever more pieces to the polygenic puzzle
-
Bogdanova N, Helbig S, Dork T. Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hered Cancer Clin Pract. 2013;11:12.
-
(2013)
Hered Cancer Clin Pract
, vol.11
, pp. 12
-
-
Bogdanova, N.1
Helbig, S.2
Dork, T.3
-
6
-
-
58849157647
-
Cowden syndrome: a critical review of the clinical literature
-
Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns. 2009;18:13–27.
-
(2009)
J Genet Couns
, vol.18
, pp. 13-27
-
-
Pilarski, R.1
-
7
-
-
0142157701
-
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype
-
Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63:6643–6650.
-
(2003)
Cancer Res
, vol.63
, pp. 6643-6650
-
-
Olivier, M.1
Goldgar, D.E.2
Sodha, N.3
-
8
-
-
0033738748
-
Will the real Cowden syndrome please stand up: revised diagnostic criteria
-
Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 2000;37:828–830.
-
(2000)
J Med Genet
, vol.37
, pp. 828-830
-
-
Eng, C.1
-
9
-
-
33744782567
-
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome
-
Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12:3209–3215.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 3209-3215
-
-
Hearle, N.1
Schumacher, V.2
Menko, F.H.3
-
10
-
-
0035211026
-
Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families
-
Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348–1353.
-
(2001)
Gastroenterology
, vol.121
, pp. 1348-1353
-
-
Pharoah, P.D.1
Guilford, P.2
Caldas, C.3
-
11
-
-
34249989159
-
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer
-
Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297:2360–2372.
-
(2007)
JAMA
, vol.297
, pp. 2360-2372
-
-
Kaurah, P.1
MacMillan, A.2
Boyd, N.3
-
12
-
-
80053100604
-
Rare variants in the ATM gene and risk of breast cancer [serial online]
-
Goldgar DE, Healey S, Dowty JG, et al. Rare variants in the ATM gene and risk of breast cancer [serial online]. Breast Cancer Res. 2011;13:R73.
-
(2011)
Breast Cancer Res
, vol.13
, pp. R73
-
-
Goldgar, D.E.1
Healey, S.2
Dowty, J.G.3
-
13
-
-
80053594059
-
Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer
-
Cybulski C, Wokolorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011;29:3747–3752.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3747-3752
-
-
Cybulski, C.1
Wokolorczyk, D.2
Jakubowska, A.3
-
14
-
-
39149141409
-
CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls
-
Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008;26:542–548.
-
(2008)
J Clin Oncol
, vol.26
, pp. 542-548
-
-
Weischer, M.1
Bojesen, S.E.2
Ellervik, C.3
Tybjaerg-Hansen, A.4
Nordestgaard, B.G.5
-
15
-
-
84908145253
-
Breast-cancer risk in families with mutations in PALB2
-
Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371:497–506.
-
(2014)
N Engl J Med
, vol.371
, pp. 497-506
-
-
Antoniou, A.C.1
Casadei, S.2
Heikkinen, T.3
-
16
-
-
84973288294
-
-
Version 2.2016. NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA NCCN, Accessed March 3, 2016
-
Daly M, Pilarski R, Axilbund JE, et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2016. NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA: NCCN; 2016. Available at: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed March 3, 2016.
-
(2016)
Genetic/Familial High-Risk Assessment: Breast and Ovarian
-
-
Daly, M.1
Pilarski, R.2
Axilbund, J.E.3
-
17
-
-
84921898753
-
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer
-
Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clinl Oncol. 2015;33:304–311.
-
(2015)
J Clinl Oncol
, vol.33
, pp. 304-311
-
-
Couch, F.J.1
Hart, S.N.2
Sharma, P.3
-
18
-
-
84965090778
-
Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment
-
Desmond A, Kurian AW, Gabree M, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 2015;1:943–951.
-
(2015)
JAMA Oncol
, vol.1
, pp. 943-951
-
-
Desmond, A.1
Kurian, A.W.2
Gabree, M.3
-
19
-
-
84930531402
-
Gene-panel sequencing and the prediction of breast-cancer risk
-
Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372:2243–2257.
-
(2015)
N Engl J Med
, vol.372
, pp. 2243-2257
-
-
Easton, D.F.1
Pharoah, P.D.2
Antoniou, A.C.3
-
20
-
-
84918798338
-
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel
-
Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121:25–33.
-
(2015)
Cancer
, vol.121
, pp. 25-33
-
-
Tung, N.1
Battelli, C.2
Allen, B.3
-
21
-
-
77957967823
-
Expanding the criteria for BRCA mutation testing in breast cancer survivors
-
Kwon JS, Daniels MS, Sun CC, Lu KH. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28:4214–4220.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4214-4220
-
-
Kwon, J.S.1
Daniels, M.S.2
Sun, C.C.3
Lu, K.H.4
-
22
-
-
84890247728
-
Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis
-
Tun NM, Villani G, Ong K, Yoe L, Bo ZM. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin Genet. 2014;85:43–48.
-
(2014)
Clin Genet
, vol.85
, pp. 43-48
-
-
Tun, N.M.1
Villani, G.2
Ong, K.3
Yoe, L.4
Bo, Z.M.5
-
23
-
-
84856770553
-
Early onset HER2-positive breast cancer is associated with germline TP53 mutations
-
Melhem-Bertrandt A, Bojadzieva J, Ready KJ, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012;118:908–913.
-
(2012)
Cancer
, vol.118
, pp. 908-913
-
-
Melhem-Bertrandt, A.1
Bojadzieva, J.2
Ready, K.J.3
-
24
-
-
78149335586
-
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations
-
Wilson JR, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet. 2010;47:771–774.
-
(2010)
J Med Genet
, vol.47
, pp. 771-774
-
-
Wilson, J.R.1
Bateman, A.C.2
Hanson, H.3
-
25
-
-
84965051096
-
Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of breast cancer patients
-
Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of breast cancer patients. J Clin Oncol. 2016;34:1460–1468.
-
(2016)
J Clin Oncol
, vol.34
, pp. 1460-1468
-
-
Tung, N.1
Lin, N.U.2
Kidd, J.3
-
26
-
-
84907597238
-
A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes
-
Eggington JM, Bowles KR, Moyes K, et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet. 2014;86:229–237.
-
(2014)
Clin Genet
, vol.86
, pp. 229-237
-
-
Eggington, J.M.1
Bowles, K.R.2
Moyes, K.3
-
27
-
-
84928209346
-
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
-
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.
-
(2015)
Genet Med
, vol.17
, pp. 405-424
-
-
Richards, S.1
Aziz, N.2
Bale, S.3
-
28
-
-
0033237314
-
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews
-
Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 1999;64:963–970.
-
(1999)
Am J Hum Genet
, vol.64
, pp. 963-970
-
-
Hartge, P.1
Struewing, J.P.2
Wacholder, S.3
Brody, L.C.4
Tucker, M.A.5
-
29
-
-
0029794992
-
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
-
Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14:185–187.
-
(1996)
Nat Genet
, vol.14
, pp. 185-187
-
-
Roa, B.B.1
Boyd, A.A.2
Volcik, K.3
Richards, C.S.4
-
30
-
-
84964999648
-
Panel testing for familial breast cancer: calibrating the tension between research and clinical care
-
Thompson ER, Rowley SM, Li N, et al. Panel testing for familial breast cancer: calibrating the tension between research and clinical care. J Clin Oncol. 2016;34:1455–1459.
-
(2016)
J Clin Oncol
, vol.34
, pp. 1455-1459
-
-
Thompson, E.R.1
Rowley, S.M.2
Li, N.3
-
31
-
-
85019281384
-
Presented Abstracts from the 33rd Annual Education Conference of the National Society of Genetic Counselors; New Orleans, LA; September 2014. Detection of pathogenic mutations in moderate penetrance breast cancer genes significantly increases the number of patients identified as candidates for increased screening [abstract]
-
Rosenthal E, McCoy H, Moyes K, Evans B, Wenstrup R. Presented Abstracts from the 33rd Annual Education Conference of the National Society of Genetic Counselors; New Orleans, LA; September 2014. Detection of pathogenic mutations in moderate penetrance breast cancer genes significantly increases the number of patients identified as candidates for increased screening [abstract]. J Genet Couns. 2014;23:1100.
-
(2014)
J Genet Couns
, vol.23
, pp. 1100
-
-
Rosenthal, E.1
McCoy, H.2
Moyes, K.3
Evans, B.4
Wenstrup, R.5
-
32
-
-
84952630873
-
Rescreening for genetic mutations using multigene panel testing in patients who previously underwent non-informative genetic screening
-
Frey MK, Kim SH, Bassett RY, et al. Rescreening for genetic mutations using multigene panel testing in patients who previously underwent non-informative genetic screening. Gynecol Oncol. 2015;139:211–215.
-
(2015)
Gynecol Oncol
, vol.139
, pp. 211-215
-
-
Frey, M.K.1
Kim, S.H.2
Bassett, R.Y.3
-
33
-
-
84952642532
-
A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients
-
Lincoln SE, Kobayashi Y, Anderson MJ, et al. A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients. J Mol Diagn. 2015;17:533–544.
-
(2015)
J Mol Diagn.
, vol.17
, pp. 533-544
-
-
Lincoln, S.E.1
Kobayashi, Y.2
Anderson, M.J.3
-
34
-
-
84885853847
-
Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress
-
Culver JO, Brinkerhoff CD, Clague J, et al. Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress. Clin Genet. 2013;84:464–472.
-
(2013)
Clin Genet
, vol.84
, pp. 464-472
-
-
Culver, J.O.1
Brinkerhoff, C.D.2
Clague, J.3
-
35
-
-
70449447725
-
Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes
-
O'Neill SC, Rini C, Goldsmith RE, Valdimarsdottir H, Cohen LH, Schwartz MD. Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. Psychooncology. 2009;18:1088–1096.
-
(2009)
Psychooncology
, vol.18
, pp. 1088-1096
-
-
O'Neill, S.C.1
Rini, C.2
Goldsmith, R.E.3
Valdimarsdottir, H.4
Cohen, L.H.5
Schwartz, M.D.6
-
36
-
-
9744252310
-
Variants of uncertain clinical significance as a result of BRCA1/2 testing: impact of an ambiguous breast cancer risk message
-
van Dijk S, van Asperen CJ, Jacobi CE, et al. Variants of uncertain clinical significance as a result of BRCA1/2 testing: impact of an ambiguous breast cancer risk message. Genet Test. 2004;8:235–239.
-
(2004)
Genet Test
, vol.8
, pp. 235-239
-
-
van Dijk, S.1
van Asperen, C.J.2
Jacobi, C.E.3
-
37
-
-
85019273134
-
Safety of multiplex gene testing for inherited cancer risk: interim analysis of a clinical trial [abstract]
-
Kurian AW, Idos G, Culver J, et al. Safety of multiplex gene testing for inherited cancer risk: interim analysis of a clinical trial [abstract]. J Clin Oncol. 2016;34(15S). Abstract 1503.
-
(2016)
J Clin Oncol
, vol.34
, Issue.15S
-
-
Kurian, A.W.1
Idos, G.2
Culver, J.3
-
38
-
-
84861323251
-
Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer
-
Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787–2795.
-
(2012)
Cancer
, vol.118
, pp. 2787-2795
-
-
Hartman, A.R.1
Kaldate, R.R.2
Sailer, L.M.3
-
39
-
-
68149168181
-
Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy [abstract]
-
Ryan PD, Tung NM, Isakoff SJ, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy [abstract]. J Clin Oncol. 2009;27(15S). Abstract 551.
-
(2009)
J Clin Oncol
, vol.27
, Issue.15S
-
-
Ryan, P.D.1
Tung, N.M.2
Isakoff, S.J.3
-
40
-
-
77949908546
-
Efficacy of neoadjuvant cisplatin in triple-negative breast cancer
-
Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145–1153.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1145-1153
-
-
Silver, D.P.1
Richardson, A.L.2
Eklund, A.C.3
|